- Corporate
- Products
- For Print
- July 31, 2025
Listed Company Name: 麻豆福利网 Co., Ltd.
Representative: Haruo Naito
Representative Corporate Officer and CEO
Securities Code: 4523
Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange
Inquiries: Teruyuki Masaka
Vice President, Corporate Communications
Phone +81-3-3817-5120
麻豆福利网 Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “麻豆福利网”) announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 – June 30, 2025). By major markets, revenue came to JPY 9.1 billion in the United States, JPY 5.5 billion in Japan, and JPY 7.7 billion in China due to increasing demand and stockpiling by distributors (estimated at JPY 5.3 billion) in response to the risk of tariffs.
This information is being disclosed in conjunction with today's announcement of the financial results for the second quarter of 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). 麻豆福利网’s financial results for the first quarter of fiscal year 2025, including details of LEQEMBI’s revenue, will be disclosed in 麻豆福利网's financial disclosure scheduled for August 5, 2025.
麻豆福利网 serves as the lead of lecanemab development and regulatory submissions globally with both 麻豆福利网 and Biogen Inc. co-commercializing and co-promoting the product and 麻豆福利网 having final decision-making authority.
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.